Sylvia Keijzer

Prematurity affects millions of families, with 1 in 10 babies born preterm. As World Prematurity Day approaches on November 17, Chiesi is launching its campaign "Unscripted Beginnings - A Fragile Start, A Strong Future", building on its 30-year commitment in Neonatology. Discover more about prematurity in the gallery. #UnscriptedBeginnings #WorldPrematurityDay #Chiesi

3

Prematurity affects millions of families, with 1 in 10 babies born preterm. As World Prematurity Day approaches on November 17, Chiesi has launched the campaign "Unscripted Beginnings - A Fragile Start, A Strong Future", building on our 30-year commitment in Neonatology. Discover more about prematurity in the gallery below. #Chiesi_USA #ChiesiGroup #UnscriptedBeginnings #WorldPrematurityDay

37

#ClimateChange is impacting global health, particularly those more vulnerable to the threats of #airpollution, such as people with respiratory conditions. At Chiesi, we strongly believe that #patients should not have to shoulder the burden of environmental responsibility when considering treatment options that affect their #health. Learn more by watching the episode “How Redesigning Inhalers Could Reduce Their Environmental Impact” sponsored by Chiesi and produced by BBC StoryWorks: https://lnkd.in/dCTQNiez #EarthDay #ActionOverWords #TheClimateAndUs

234

At Chiesi, we are committed to providing innovative solutions that enhance the customer experience (CX). Utilizing cutting-edge technologies and pioneering innovations, we purposefully strive to set new benchmarks within the industry by embracing collaborative efforts with key opinion leaders in the neonatology space. In collaboration with our customers, we developed NeoCarePal, to support physicians, nurses, and therapists in their daily practice.     NeoCarePal (NCP) is a resource providing access to multiple clinical calculations in one place, saving Healthcare Providers (HCPs) time searching for valid resources. All NCP calculators are based on established guidelines and clearly referenced scientific evidence. No internet connection is required for using the calculators. However, links to other useful calculators and resources available online are provided in the app to ensure HCPs have all they need at their fingertips. This application is intended for use by HCPs as a support tool. It does not provide therapeutic or diagnostic assistance and it is not a substitute for clinical judgment.     Are you a Healthcare Provider? Check it out in the app store!  - Apple: https://lnkd.in/g-AmNigQ   - Android/Google Play: https://lnkd.in/ggjTpfvn    #Chiesi_USA #LifeinChiesi #CX #CareBeyondTreatment #Innovation

45

Fantastic days at the #EADVCongress with our #EFACommunity! Engaged in insightful discussions and shared our commitment to advancing care for #atopiceczema patients across Europe. Let’s focus on some key areas where European policymakers can drive change: 🚨 Access to #Care: Timely access to multidisciplinary care is crucial for atopic eczema patients, especially those with severe symptoms. This includes #dermatologists, #psychologists, allergologists, and more. 🔬 Research & Innovation: We need more EU funding to understand the causes of #AtopicEczema, develop better treatments, and enhance quality of life. Every advance can make a significant difference in patients future! 📊 Patient Data: Real-world data is essential for improving treatments. National registries must be established to collect high-quality data and support new therapies. #DataForPatients 📺 Watch more in our Call to Action to European policymakers: https://lnkd.in/eYG7fnDq 📑 And read our #AtopicEczemaBurden Report in your language: https://lnkd.in/ehwWTXGH European Academy of Dermatology and Venereology #atopicdermatitis #skin #chronicskindiseases

23

2 comentarios

#Uprising We are thrilled to announce that Zambon recently become a part of #PharmaSynergyOTC 2024! PharmaSynergyOTC, a global event taking place on September 12-13 at Les Salons Hoche in Paris, presents a unique opportunity for companies specializing in OTC and consumer health products to connect, learn, and engage in discussions about commercial partnerships. We believe that in the dynamic landscape of pharmaceuticals and consumer healthcare, networking is about meaningful connections. At PharmaSynergy OTC events, our focus is clear: Over-the-counter, Consumer Healthcare, Nutraceuticals, Dermocosmetics, and Medical Devices (OTC). This targeted approach ensures that every interaction is purposeful, leading to fruitful connections, discussions and collaborations. For registration details, please visit our website at https://lnkd.in/gFtazD6 or get in touch via [email protected] #NOT_JUST_ANOTHER_EVENT #PRODUCT_FOCUSED_PARTNERING_EVENT #Over_the_Counter #OTC #ConsumerHealthcare #CHC #Dermocosmetics #OTCmedicaldevices #FSMP #BusinessDevelopment #B2Bpartnering #Distribution #Efficient_B2B_Partnering #therapeutic_indication #geographical_presence #collaboration_type #Growth_stimulating_Insights #trends #growthOpportunities #analytics #growth_pockets

7

Every year, more than 50,000 cases of myeloma are diagnosed in Europe 🩸 On #EuropeanMyelomaDay, we applaud the dedication of Myeloma Patients Europe (MPE) Europe in leading efforts to improve: ➡️ patient experience ➡️ prognosis ➡️ overall quality of life The focus 🔍 for this year: clinical trials & the challenges of clinical trial access. Learn more 🔗 https://lnkd.in/dZM-EyKK

8

1 comentario

Ovarian cancer is the eighth leading cause of #death due to #cancer in women. People affected by ovarian cancer often experience relapses, and then need to be treated with 𝘃𝗮𝗿𝗶𝗼𝘂𝘀 𝗹𝗶𝗻𝗲𝘀 𝗼𝗳 #𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁. Daniela Luvero, Roberto Angioli, Maria Elena Spoltore, Fernando Ficarola, 𝗟𝗮𝘂𝗿𝗮 𝗙𝗲𝗼𝗹𝗲, Francesco Plotti, 𝗖𝗼𝗿𝗿𝗮𝗱𝗼 𝗧𝗲𝗿𝗿𝗮𝗻𝗼𝘃𝗮, 𝗖𝗮𝗿𝗹𝗼 𝗗𝗲 𝗖𝗶𝗰𝗰𝗼 𝗡𝗮𝗿𝗱𝗼𝗻𝗲, 𝗙𝗲𝗱𝗲𝗿𝗶𝗰𝗮 𝗚𝘂𝘇𝘇𝗼, Roberto Montera aimed to investigate the effectiveness of #letrozole in patients with relapsed advanced ovarian cancer already subjected to multiple lines of treatment and #chemotherapy was no longer the option of choice. Letrozole is associated with 𝗴𝗼𝗼𝗱 𝗣𝗮𝘁𝗶𝗲𝗻𝘁𝘀-𝗙𝗿𝗲𝗲-𝗦𝘂𝗿𝘃𝗶𝘃𝗮𝗹 𝗮𝗻𝗱 𝗶𝗻𝗰𝗿𝗲𝗮𝘀𝗲𝗱 𝗢𝘃𝗲𝗿𝗮𝗹𝗹 𝗦𝘂𝗿𝘃𝗶𝘃𝗮𝗹 in patients for which other chemotherapeutic options are no longer eligible.

17

We are committed to supporting the real needs of pharmacists in every market we serve, and our approach in Germany is no exception. Mrs. Selda Kubilay, our Brand Equity Manager based in Germany, shares valuable insights on why understanding these needs is crucial for our operations. https://lnkd.in/d2HWHUhZ 💡 Tailored Support: We ensure that our support aligns precisely with the actual requirements of pharmacists.  🎯 Reliability and Availability: Our priority is to maintain the highest level of delivery reliability and product availability, ensuring that healthcare professionals can rely on us when it matters most.  🚚 Fast Transportation: Given that the medications are manufactured in Europe, it facilitates swift transportation to Germany and other European markets, mitigating any delivery constraints. Mrs. Kubilay also highlighted our roots and global presence. Headquartered in Heppenheim, Germany since 2022, ABDI FARMA is part of the storied ABDI IBRAHIM family, a pharmaceutical leader founded nearly a century ago in Turkey and now serving over 60 countries worldwide. Discover More on YouTube:  For deeper insights into our patient-centric approaches and advanced healthcare technologies, visit our YouTube channel:  https://lnkd.in/dNJRwaHJ #AbdiFarma #PharmainGermany #Pharmacists #Apothekerinnen

69

Chiesi Group and Oak Hill Bio have announced that the first patient has enrolled for the resumed Phase 2b clinical study evaluating OHB-607 for the potential prevention of Bronchopulmonary Dysplasia, the most common cause of Chronic Lung Disease in premature infants. This is a significant advancement in the shared mission of our companies with a treatment that has the potential to be the first innovative respiratory therapeutic advance for extremely preterm neonates in over thirty years. Diego Ardigò, Global Research & Development Head at Chiesi Group, comments on this new clinical trial and the company’s commitment to advancing neonatology. Read more here: https://lnkd.in/grBwSU5D #Chiesi_USA #Respiratory #Neonatology #Partnership #ClinicalStudy 

139

Have you got your copy of our IMAS Global Report? Pick up your copy at our EULAR - European Alliance of Associations for Rheumatology Booth 05 today! We are looking forward to seeing you! #axSpA #AxialSpondyloarthritis #rheumatology

10

🔎🩺Discover the key insights on Notified Body capacity and IVDR harmonization from Marta Carnielli and ANDREAS STANGE. How is the current landscape evolving? What are the challenges and solutions? Watch our video to get the latest updates and expert advice. #IVDR #Regulation #NotifiedBody #MedTech

53

5 comentarios

Patiromer Proven Cost-Effective in Managing Hyperkalemia for Chronic Kidney Disease Patients in Italy A study examined the cost-effectiveness of patiromer, a treatment for hyperkalemia

5

Have you explored our new Challenge with Angelini Pharma? This new Open Innovation opportunity to identify new innovative Drug Delivery Systems (DDS) and Treatment Approaches will help to significantly improve the lives of people with epilepsy. Check out this post from Rafal Kaminski and learn more details about this Challenge: https://bit.ly/3XIET9Y #OpenInnovation #WazokuCrowd #epilepsy #angelinipharma #everystepcloser #withyouinmind

6

Success Story – Discover the Transformation of Medical Treatment Through the Power of Open Innovation   medac GmbH, in collaboration with ekipa, launched the "Innovate Rheumatology" challenge to develop smart, personalized solutions in rheumatology. Personalized medicine requires tailoring treatments to individual genetic, environmental, and lifestyle factors through extensive data analysis and advanced technologies. We spoke with Dr. Claas Cassens from medac about the groundbreaking outcomes of this Open Innovation Challenge.   Watch the video to discover: ✅ How Open Innovation is key to overcoming operational blind spots and breaking free from routine tasks. ✅ The transformative collaboration with the winning teams. ✅ Insights on using OI to adopt complex innovations like personalized medicine and digitalization. ✅ The role of ekipa and it’s network in driving the challenge's success.   Dive into our comments for more about the “Innovate Rheumatology” Challenge with medac!   Are you interested in how Open Innovation can address complex challenges in your field? Contact Justin Gemeri for more information on initiating an Open Innovation project with ekipa.   A huge thanks to the teams and their great commitment, Laura Stella Korcik (Vila Health), Camille Bouget, Vincent Bouget, Julien Duquesne (Scienta Lab), Carlo Alberto Paggi, PhD, Dustin Dopsa (chiron), Gernot Sümmermann & Manuel Wessely (Cynteract GmbH)!

18

2 comentarios

Visit ProSciento at European Association for the Study of Diabetes e.V. (EASD) 2024 in booth E13 or schedule a meeting: https://bit.ly/4ce71W6. As the leading CRO in metabolic diseases, we deliver tailored services and solutions for every phase of your #diabetes research journey. From study initiation, participant recruitment, and site engagement to data analysis and study wrap-up, we offer complete support. Don’t miss the chance to connect with our experts and discover how we can advance your diabetes research program! #EASD2024 #MetabolicDiseases #ClinicalTrials #DiabetesResearch #DiabetesCRO #Type1Diabetes #Type2Diabetes #MetabolicContinuum #ScienceDriven #PatientFocused

27

For many years, Stratenym has been supporting clients with market access strategy in a way that closely follows the key suggestions outlined in Mario Draghi's report. We have found that aligning with EU regulations and optimising evidence strategies for our clients results in positive recommendations as payers increasingly adopt a holistic view of the value chain, following the trend highlighted by Mario Draghi. #MarketAccess

4